申请人:Merck & Co., Inc.
公开号:US05652257A1
公开(公告)日:1997-07-29
The present invention comprises analogs of the CAAX motif of the protein Ras that is modified by farnesylation in vivo. These CAAX analogs inhibit the farnesylation of Ras. Furthermore, these CAAX analogues differ from those previously described as inhibitors of Ras farnesyl transferase in that they do not have a thiol moiety. The lack of the thiol offers unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependent chemical reactions, such as rapid autoxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity. Further contained in this invention are chemotherapeutic compositions containing these farnesyl transferase inhibitors and methods for their production.
本发明包括蛋白质Ras的CAAX基序的类似物,该基序在体内通过法尼酰化进行修饰。这些CAAX类似物抑制了Ras的法尼酰化。此外,这些CAAX类似物与以前描述的抑制Ras法尼基转移酶的类似物不同,因为它们不具有硫醇基团。缺乏硫醇基团在改善动物体内药代动力学行为、预防硫醇依赖的化学反应(如快速自氧化和与内源硫醇的二硫键形成)以及减少系统毒性方面提供了独特优势。此外,本发明还包括含有这些法尼基转移酶抑制剂的化疗组合物和其生产方法。